DALLAS, March 11, 2021 — When NA1, a neuroprotectant, was delivered to the brain in nanoparticles, it reduced stroke severity and improved survival in a mouse model of stroke, according to preliminary research to be presented at the American Stroke Association’s International Stroke Conference 2021. The virtual meeting is March 17-19, 2021 and is a world premier meeting for researchers and clinicians dedicated to the science of stroke and brain health.
In an earlier human trial (the ESCAPE-NA1 trial), NA1, a small peptide designed to save brain cells from death after stroke, showed mixed results when NA1 was administered to patients undergoing clot removal for severe stroke. Some patients in the trial also received the intravenous clot-busting medication tissue plasminogen activator (tPA), and these patients in particular showed a lack of improvement in functional outcomes from NA1.
“NA1 binds many organs, cells and proteins in the body. Without protection, it cannot get into the brain with high efficiency and specificity and may otherwise get into cells where we don’t want it, or bind and deactivate other treatments, such as the clot-busting medicine tPA,” said Jiangbing Zhou, Ph.D., co-senior author of the study and associate professor of neurosurgery and biomedical engineering at Yale University in New Haven, Connecticut.
To deliver NA1 precisely where it is needed, the research team in this study created stroke-targeting nanoparticles to encapsulate and deliver NA1 to portions of the brain being deprived of oxygen in a stroke mouse model.
In the mouse model study conducted from 2016 to 2020, researchers compared the ability of nanoparticles filled with NA1 and non-encapsulated NA1 to improve survival, reduce stroke size and reduce brain swelling. Both treatments contained the same dose of NA1 (50 micrograms) delivered intravenously to mice with blockage of a brain artery.
Researchers found:
- Stroke size was reduced 69.8% among mice treated with NA1-loaded nanoparticles, compared with 0.7% for those treated with NA1 that was not encapsulated.
- Brain swelling was reduced 60.3% among mice treated with NA1-loaded nanoparticles, compared with 3.3% for those treated with NA1 that was not encapsulated.
- Median days of survival were more than 14 days among mice treated with NA1-loaded nanoparticles (mice in this model usually survive significantly less than 14 days), compared to 6 days for those treated with NA1 that was not encapsulated.
“When delivered by nanoparticles, the same dose of NA1 that was not effective in an earlier study reached the stroke area and provided a surprising degree of effectiveness. The use of nanoparticles in stroke treatment may open new doors to delivering NA1 and other promising therapies to the brain,” said Kevin N. Sheth, M.D., co-senior author of the study and professor of neurology and neurosurgery at Yale University.
Since the nanoparticles themselves act as antioxidants and may improve stroke outcome, some of the mice were also treated with nanoparticles not containing NA1. Those mice had intermediate improvements: stroke size reduced by 52.2%, brain swelling reduced by 30.2% and a median survival of 10 days.
“We have not had any recent major advances in the delivery of brain-protective agents for stroke. These results suggest a significant effort to change that landscape,” Sheth said.
###
Additional co-authors are Shenqi Zhang, M.D., Ph.D.; Zeming Chen, Ph.D.; Gang Deng, M.D., Ph.D.; W. Taylor Kimberly, M.D., Ph.D.; and J. Marc Simard, M.D. Author disclosures are listed in the abstract.
The study was funded by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health and the American Heart Association.
Additional Resources:
Multimedia is available on the right column of release link https:/
Types of stroke
Stroke Treatments
For more news at ASA International Stroke Conference 2021, follow us on Twitter @HeartNews #ISC21.
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association’s overall financial information is available here.
The American Stroke Association’s International Stroke Conference (ISC) is the world’s premier meeting dedicated to the science and treatment of cerebrovascular disease. ISC 2021 will be held virtually, March 17-19, 2021. This 3-day conference will feature more than 1,200 compelling presentations in 21 categories that emphasize basic, clinical and translational sciences as they evolve toward a better understanding of stroke pathophysiology with the goal of developing more effective therapies. Engage in the International Stroke Conference on social media via #ISC21.
About the American Stroke Association
The American Stroke Association is devoted to saving people from stroke — the No. 2 cause of death in the world and a leading cause of serious disability. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat stroke. The Dallas-based association officially launched in 1998 as a division of the American Heart Association. To learn more or to get involved, call 1-888-4STROKE or visit stroke.org. Follow us on Facebook, Twitter.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
